Edward M. Kaye MD - 04 Sep 2025 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Reporting relationship: Director
Issuer ticker: STOK
Reported as of: 04 Sep 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Sep 2025, 16:10:22 UTC
Prior SEC filing: 02 Sep 2025
Next SEC filing: 30 Sep 2025
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Allan, Attorney-in-Fact

Key filing fact

Edward M. Kaye MD filed Form 4 for Stoke Therapeutics, Inc. (STOK) on 05 Sep 2025.

Key facts

This page summarizes Edward M. Kaye MD's Form 4 filing for Stoke Therapeutics, Inc. (STOK).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 05 Sep 2025, 16:10.

Change

Previous filing in this sequence was filed on 02 Sep 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001522780 Primary reporting owner

Kaye Edward M. MD

Relationship: Director
Address: C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD
Signature: /s/ Jonathan Allan, Attorney-in-Fact
Signature date: 05 Sep 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

STOK transaction Derivative

Employee Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -178,500
Change %: -83%
Price: $0.000000
Shares after: 37,500
Date: 04 Sep 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 178,500
Exercise price: $8.33
Footnotes: F1, F2

STOK transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value: $0
Shares: -144,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 04 Sep 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 144,000
Exercise price
Footnotes: F3, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The reported transaction represents a disposition to the Issuer of equity securities that is exempt pursuant to Rule 16b-3(e) and 16b-6(d). The equity award was partially canceled for no consideration by mutual agreement of the reporting person and the Issuer.

Footnote F2

The option began vesting on April 15, 2025. Pursuant to the terms of the initial grant, the original number of shares subject to the option vests in ratable increments monthly and the option shall be fully vested on December 15, 2026, subject to the reporting person's continued service to the Issuer through each vesting date.

Footnote F3

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.

Footnote F4

The reported transaction represents a disposition to the Issuer of equity securities that is exempt pursuant to Rule 16b-3(e) and 16b-6(d). The entire equity award was canceled for no consideration by mutual agreement of the reporting person and the Issuer.

Footnote F5

Pursuant to the terms under which it was granted, the award was scheduled to vest as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the Issuer through each vesting date.